J Korean Diabetes > Volume 15(3); 2014 > Article
The Journal of Korean Diabetes 2014;15(3):158-162.
DOI: https://doi.org/10.4093/jkd.2014.15.3.158    Published online September 30, 2014.
SGLT2 억제제의 부작용
김원진, 김상수
The Side Effects of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitor.
Won Jin Kim, Sang Soo Kim
Department of Internal Medicine, Pusan National University Hospital, Busan, Korea. drsskim7@gmail.com
Abstract
Anti-diabetic drugs for effectively lowering glucose with limited side effects are necessary in providing patient-centered diabetic management. Sodium glucose cotransporter 2 (SGLT 2) inhibitors provide a novel therapeutic approach for managing type 2 diabetic patients by lowering glucose levels by increasing urinary excretion of glucose independently of insulin secretion or action. Several SGLT 2 inhibitors were recently approved and available in the US, European and Korean markets. SGLT 2 improved glycemic control with low propensity of hypoglycemia. Through the clinical trials, most SLGT2 inhibitors were generally well tolerated. Genital tract infections were more frequent in most clinical studies of SGLT2 inhibitors and urinary tract infections were slightly increased in some studies. This review will describe the main safety issues that have been uncovered in clinical trials of SGLT 2 inhibitors.
Key Words: Type 2 diabetes mellitus, Sodium glucose cotransporter 2, Safety


Editorial Office
101-2104, Lotte Castle President, 109 Mapo-daero, Mapo-gu, Seoul 04146, Korea​
Tel: +82-2-714-9064    Fax: +82-2-714-9084    E-mail: diabetes@kams.or.kr                

Copyright © 2022 by Korean Diabetes Association. All rights reserved.

Developed in M2PI

Close layer